CymaBay Therapeutics (CBAY) News Today → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free CBAY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 6, 2024 | marketbeat.comVanguard Group Inc. Purchases 598,707 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Vanguard Group Inc. lifted its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 11.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 5,747,587 shares of the biopharmaceutical company's stock after acquiring an additional 598,7April 3, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Earns Sell Rating from Analysts at StockNews.comStockNews.com initiated coverage on CymaBay Therapeutics in a research note on Wednesday. They issued a "sell" rating on the stock.March 28, 2024 | marketbeat.comAssenagon Asset Management S.A. Invests $17.63 Million in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Assenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 746,353 shares of the biopMarch 22, 2024 | za.investing.comGilead reduces 2024 earnings guidance after completing CymaBay takeoverMarch 22, 2024 | markets.businessinsider.comGilead Sciences Completes Acquisition Of CymaBay TherapeuticsMarch 22, 2024 | businesswire.comGilead Sciences Announces Completion of Acquisition of CymaBayMarch 22, 2024 | marketbeat.comTrading was temporarily halted for "CBAY" at 07:03 PM with a stated reason of "News pending."March 22, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Sold by Deutsche Bank AGDeutsche Bank AG cut its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 44.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 456,106 shares of the biopharmaceutical company's stock afterMarch 18, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Reaches New 52-Week High at $32.48CymaBay Therapeutics (NASDAQ:CBAY) Sets New 1-Year High at $32.48March 16, 2024 | finance.yahoo.comCBAY Jul 2024 34.000 callMarch 16, 2024 | finance.yahoo.comCBAY Apr 2024 31.000 putMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 33.000 callMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 29.000 putMarch 14, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Sees Significant Drop in Short InterestCymaBay Therapeutics, Inc. (NASDAQ:CBAY - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 29th, there was short interest totalling 5,850,000 shares, a drop of 30.1% from the February 14th total of 8,370,000 shares. Based on an average daily volume of 3,630,000 shares, the days-to-cover ratio is currently 1.6 days.March 11, 2024 | finance.yahoo.comInvesting in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gainMarch 10, 2024 | marketbeat.comGlenmede Trust Co. NA Buys Shares of 37,894 CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Glenmede Trust Co. NA bought a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,894 shares of the biopharmaceutical company's stock, valued at appMarch 9, 2024 | marketbeat.comSeven Eight Capital LP Purchases Shares of 41,556 CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Seven Eight Capital LP purchased a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,556 shares of the biopharmaceutiMarch 5, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Position Lessened by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. trimmed its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 6.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,125,000March 4, 2024 | globenewswire.comCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary CholangitisMarch 1, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Sets New 1-Year High at $32.35CymaBay Therapeutics (NASDAQ:CBAY) Sets New 52-Week High at $32.35March 1, 2024 | marketbeat.com610,770 Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Acquired by MPM Bioimpact LLCMPM Bioimpact LLC bought a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 610,770 shares of the biopharmaceutical companMarch 1, 2024 | marketbeat.comHC Wainwright Equities Analysts Lower Earnings Estimates for CymaBay Therapeutics, Inc. (NASDAQ:CBAY)CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) - Investment analysts at HC Wainwright reduced their FY2028 earnings per share estimates for shares of CymaBay Therapeutics in a note issued to investors on Thursday, February 29th. HC Wainwright analyst E. Arce now anticipates that the biophFebruary 29, 2024 | markets.businessinsider.comMaintaining Hold on CymaBay Amid Gilead Acquisition Deal ClosureFebruary 29, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CymaBay Therapeutics, Inc. (CBAY)February 29, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "neutral" rating and set a $32.50 price target on shares of CymaBay Therapeutics in a research note on Thursday.February 28, 2024 | marketwatch.comCymaBay Therapeutics 4Q Loss/Shr 35c >CBAYFebruary 28, 2024 | globenewswire.comCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | marketbeat.comAlgert Global LLC Purchases New Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Algert Global LLC purchased a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 92,886 shares of the biopharmaceutical companFebruary 25, 2024 | marketbeat.comMonashee Investment Management LLC Acquires New Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Monashee Investment Management LLC acquired a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 75,000 shares of the biopharmFebruary 24, 2024 | msn.comCymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37February 23, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Purchased by Swiss National BankSwiss National Bank increased its stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 14.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 181,500 shares of the biopharmaceutical company's stock after purFebruary 22, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Stake Lessened by Deutsche Bank AGDeutsche Bank AG cut its holdings in CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 44.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 456,106 shares of the biopharmaceutical company's stock after selling 369,851 shares during the peFebruary 21, 2024 | finance.yahoo.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 21, 2024 | prnewswire.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 20, 2024 | msn.comLeerink Partners Downgrades CymaBay Therapeutics (CBAY)February 20, 2024 | globenewswire.comCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 20, 2024 | marketbeat.comClariVest Asset Management LLC Sells 63,600 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)ClariVest Asset Management LLC lowered its stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 39.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 96,481 shares of the biopharmFebruary 20, 2024 | marketbeat.comSVB Leerink Reaffirms Market Perform Rating for CymaBay Therapeutics (NASDAQ:CBAY)SVB Leerink restated a "market perform" rating and issued a $32.50 target price on shares of CymaBay Therapeutics in a research note on Tuesday.February 18, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Acquired by New York State Common Retirement FundNew York State Common Retirement Fund lifted its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 39.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,4February 16, 2024 | businesswire.comCYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAYFebruary 15, 2024 | marketbeat.comFY2026 Earnings Forecast for CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Issued By HC WainwrightCymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) - Research analysts at HC Wainwright raised their FY2026 EPS estimates for CymaBay Therapeutics in a note issued to investors on Tuesday, February 13th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will postFebruary 15, 2024 | finance.yahoo.comCBAY Jan 2026 37.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Feb 2024 33.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Jan 2025 8.000 putFebruary 14, 2024 | marketbeat.comAnalysts Offer Predictions for CymaBay Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:CBAY)CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) - Equities researchers at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for CymaBay Therapeutics in a note issued to investors on Tuesday, February 13th. HC Wainwright analyst E. Arce forecasts that the biopharmaceuticaFebruary 14, 2024 | marketbeat.comAnalysts see over 50% gains in these 2 mid-cap biotech stocks (CBAY)The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.February 14, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Earns Market Perform Rating from Lifesci CapitalLifesci Capital reissued a "market perform" rating on shares of CymaBay Therapeutics in a report on Wednesday.February 13, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Sees Strong Trading VolumeCymaBay Therapeutics (NASDAQ:CBAY) Sees Unusually-High Trading VolumeFebruary 13, 2024 | seekingalpha.comCymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver FranchiseFebruary 13, 2024 | marketbeat.comBTIG Research Reiterates Neutral Rating for CymaBay Therapeutics (NASDAQ:CBAY)BTIG Research reaffirmed a "neutral" rating on shares of CymaBay Therapeutics in a report on Tuesday. Get CymaBay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter. Email Address It's time to ween off Chinese lithium! (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely Learn how this American company is leading the lithium-ion revolution CBAY Media Mentions By Week CBAY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CBAY News Sentiment▼0.000.77▲Average Medical News Sentiment CBAY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CBAY Articles This Week▼05▲CBAY Articles Average Week Get CymaBay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Mirum Pharmaceuticals News Avid Bioservices News G1 Therapeutics News Rigel Pharmaceuticals News BioMarin Pharmaceutical News BeiGene News Viatris News Sarepta Therapeutics News United Therapeutics News Dr. Reddy's Laboratories News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CBAY) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored